Dar Al Dawa Development and Investment (AMM:DADI) Altman Z-Score: 1.67 (As of Jul. 02, 2026) — 31% Above Median


AMM:DADI Dar Al Dawa Development and Investment AMM:DADI
77 GF Score
Price JOD1.14
GF Value JOD1.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Dar Al Dawa Development and Investment Altman Z-Score?

Dar Al Dawa Development and Investment AMM:DADI 77 Altman Z-Score is 1.67 as of Jul. 02, 2026, which is 31% above its 10-year median of 1.27. GuruFocus rates AMM:DADI with a GF Score™ of 77/100 and a GF Value™ of JOD1.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 951 Drug Manufacturers companies, Dar Al Dawa Development and Investment ranks worse than 73.19% on this metric.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.67 is in distress zone. This implies bankruptcy possibility in the next two years.

Dar Al Dawa Development and Investment has a Altman Z-Score of 1.67, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Dar Al Dawa Development and Investment's Altman Z-Score or its related term are showing as below:

AMM:DADI' s Altman Z-Score Range Over the Past 10 Years
Min: -0.06   Med: 1.27   Max: 1.96
Current: 1.67

During the past 13 years, Dar Al Dawa Development and Investment's highest Altman Z-Score was 1.96. The lowest was -0.06. And the median was 1.27.


Dar Al Dawa Development and Investment  (AMM:DADI) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Dar Al Dawa Development and Investment Altman Z-Score Related Terms


Dar Al Dawa Development and Investment Altman Z-Score Historical Data

* Premium members only.

The historical data trend for Dar Al Dawa Development and Investment's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dar Al Dawa Development and Investment Altman Z-Score Chart

Dar Al Dawa Development and Investment Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.16 1.18 1.43 1.41 1.65

Dar Al Dawa Development and Investment Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.44 1.36 1.65 1.70

AMM:DADI vs ZTS, UTHR, VTRS: Altman Z-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dar Al Dawa Development and Investment Altman Z-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Dar Al Dawa Development and Investment's Altman Z-Score falls into.


AMM:DADI
77GF Score
Dar Al Dawa Development and Investment AMM:DADI
Altman Z-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dar Al Dawa Development and Investment Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Dar Al Dawa Development and Investment's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2131+1.4*0.108+3.3*0.0702+0.6*0.7948+1.0*0.5505
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was JOD142.46 Mil.
Total Current Assets was JOD99.79 Mil.
Total Current Liabilities was JOD69.43 Mil.
Retained Earnings was JOD15.38 Mil.
Pre-Tax Income was 0.874 + 3.986 + 0.148 + 1.167 = JOD6.18 Mil.
Interest Expense was -0.831 + -0.981 + -1.003 + -1.009 = JOD-3.82 Mil.
Revenue was 15.068 + 25.526 + 18.723 + 19.111 = JOD78.43 Mil.
Market Cap (Today) was JOD57.00 Mil.
Total Liabilities was JOD71.72 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(99.786 - 69.432)/142.455
=0.2131

X2=Retained Earnings/Total Assets
=15.379/142.455
=0.108

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(6.175 - -3.824)/142.455
=0.0702

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=57.000/71.719
=0.7948

X5=Revenue/Total Assets
=78.428/142.455
=0.5505

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Dar Al Dawa Development and Investment has a Altman Z-Score of 1.67 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of 1.67 mean?
Dar Al Dawa Development and Investment (AMM:DADI) has a Altman Z-Score of 1.67 as of Jul. 02, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Dar Al Dawa Development and Investment and its competitors. This is 31% above median its historical median of 1.27. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #696 out of 951 companies in the Drug Manufacturers industry, placing it in the top 73.2%.
Is Dar Al Dawa Development and Investment's Altman Z-Score too high?
Dar Al Dawa Development and Investment's current Altman Z-Score of 1.67 is 31% above median its 10-year median of 1.27. The Drug Manufacturers industry median Altman Z-Score is 3.23. Dar Al Dawa Development and Investment's value of 1.67 is 48.3% below this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #696 out of 951 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #696 out of 951 companies for Altman Z-Score. This places Dar Al Dawa Development and Investment in the lower half of its industry. The industry median Altman Z-Score is 3.23. Dar Al Dawa Development and Investment's value of 1.67 is 48.3% below this benchmark. While the company's 10-year median is 1.27 vs. the industry median of 3.23, Dar Al Dawa Development and Investment has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.23, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current Altman Z-Score of 1.67 is 48.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current Altman Z-Score is 1.67, which is 31% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.10, compared to a current price of JOD1.14 — trading 3.6% above its estimated fair value. The current Altman Z-Score is 1.67, which is 31% above median its 10-year median of 1.27 and 48.3% below the Drug Manufacturers industry median of 3.23. Dar Al Dawa Development and Investment's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current Altman Z-Score is 1.67 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?

Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued. The current stock price of JOD1.14 is trading 3.6% above its estimated GF Value™ of JOD1.10. GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.

Key valuation signals for AMM:DADI:

  • Altman Z-Score: 1.67 (31% above median its 10-year median of 1.27)
  • GF Value™: JOD1.10 vs. price of JOD1.14 (3.6% above fair value)
  • GF Score™: 77/100 with 4 warning signs
  • Industry Position: 48.3% below the Drug Manufacturers median (#696 of 951)

No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dar Al Dawa Development and Investment Business Description

Address Naour, P.O. Box 9364, Amman, JOR, 11191
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
77GF Score

Get the complete analysis for AMM:DADI

Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD1.14
Price
JOD1.10
GF Value